Edward J Tanner1, Olga T Filippova2, Ginger J Gardner3, Kara C Long Roche3, Yukio Sonoda3, Oliver Zivanovic3, Mary Fischer4, Dennis S Chi3. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. Electronic address: etanner4@jhmi.edu. 2. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. 3. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States of America. 4. Department of Anesthesia, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
Abstract
OBJECTIVES: Our objective was to determine the safety and efficacy of acute normovolemic hemodilution (ANH) to reduce the requirement for allogenic red blood cell (RBC) transfusions in patients undergoing primary cytoreduction for advanced ovarian cancer. METHODS: Patients undergoing primary cytoreduction for advanced ovarian cancer were enrolled in a prospective trial assessing ANH at time of surgery. Intraoperative blood withdrawal was performed to a target hemoglobin of 8.0 g/dL. A standardized transfusion protocol first using autologous then allogenic blood was applied intraoperatively and throughout hospitalization according to institutional guidelines. The primary endpoint was to determine the overall rate of allogenic RBC transfusions in the intra- and postoperative periods. A predetermined allogenic RBC transfusion rate <35% was deemed a meaningful reduction from a 50% transfusion rate in historical controls. RESULTS: Forty-one patients consented to participate. Median blood withdrawn during ANH was 1650 mL (range, 700-3000). Cytoreductive outcomes were as follows: 0 mm, 30 (73%); 1-10 mm, 8 (20%); and >10 mm, 3 (7%) residual disease. Estimated blood loss was 1000 mL (range, 150-2700). Fourteen patients (34%) received allogenic RBC transfusions intra- or postoperatively, meeting the primary endpoint. No patients were transfused outside protocol guidelines. The rate of ≥grade 3 complications (20%) and anastomotic leaks (7%) were similar to historical controls and met predefined safety thresholds. CONCLUSIONS: For patients with advanced ovarian cancer undergoing primary cytoreductive surgery, ANH appears to reduce allogenic RBC transfusion rates versus historical controls without increasing perioperative complications. Further evaluation of the technique is warranted.
OBJECTIVES: Our objective was to determine the safety and efficacy of acute normovolemic hemodilution (ANH) to reduce the requirement for allogenic red blood cell (RBC) transfusions in patients undergoing primary cytoreduction for advanced ovarian cancer. METHODS:Patients undergoing primary cytoreduction for advanced ovarian cancer were enrolled in a prospective trial assessing ANH at time of surgery. Intraoperative blood withdrawal was performed to a target hemoglobin of 8.0 g/dL. A standardized transfusion protocol first using autologous then allogenic blood was applied intraoperatively and throughout hospitalization according to institutional guidelines. The primary endpoint was to determine the overall rate of allogenic RBC transfusions in the intra- and postoperative periods. A predetermined allogenic RBC transfusion rate <35% was deemed a meaningful reduction from a 50% transfusion rate in historical controls. RESULTS: Forty-one patients consented to participate. Median blood withdrawn during ANH was 1650 mL (range, 700-3000). Cytoreductive outcomes were as follows: 0 mm, 30 (73%); 1-10 mm, 8 (20%); and >10 mm, 3 (7%) residual disease. Estimated blood loss was 1000 mL (range, 150-2700). Fourteen patients (34%) received allogenic RBC transfusions intra- or postoperatively, meeting the primary endpoint. No patients were transfused outside protocol guidelines. The rate of ≥grade 3 complications (20%) and anastomotic leaks (7%) were similar to historical controls and met predefined safety thresholds. CONCLUSIONS: For patients with advanced ovarian cancer undergoing primary cytoreductive surgery, ANH appears to reduce allogenic RBC transfusion rates versus historical controls without increasing perioperative complications. Further evaluation of the technique is warranted.
Authors: G Sanders; N Mellor; K Rickards; A Rushton; I Christie; J Nicholl; A Copplestone; K Hosie Journal: Br J Anaesth Date: 2004-10-01 Impact factor: 9.166
Authors: Susannah M Mourton; Larissa K Temple; Nadeem R Abu-Rustum; Mary L Gemignani; Yukio Sonoda; Bernard H Bochner; Richard R Barakat; Dennis S Chi Journal: Gynecol Oncol Date: 2005-09-08 Impact factor: 5.482
Authors: William R Jarnagin; Mithat Gonen; Shishir K Maithel; Yuman Fong; Michael I D'Angelica; Ronald P Dematteo; Florence Grant; David Wuest; Kuhali Kundu; Leslie H Blumgart; Mary Fischer Journal: Ann Surg Date: 2008-09 Impact factor: 12.969
Authors: Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat Journal: Gynecol Oncol Date: 2009-04-23 Impact factor: 5.482
Authors: Thomas Boerner; Edward Tanner; Olga Filippova; Qin C Zhou; Alexia Iasonos; William P Tew; Roisin E O'Cearbhaill; Rachel N Grisham; Ginger J Gardner; Yukio Sonoda; Nadeem R Abu-Rustum; Oliver Zivanovic; Kara Long Roche; Anoushka M Afonso; Mary Fischer; Dennis S Chi Journal: Gynecol Oncol Date: 2020-11-17 Impact factor: 5.482